Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tysabri Re-Launch Timing Will Depend On Outcome Of Risk Management Plan

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen Idec/Elan could be prepared to get the multiple sclerosis drug back on the market within weeks of re-approval.

You may also be interested in...



Tysabri Re-Launch Approved With MRI Requirement

FDA clears Biogen Idec’s multiple sclerosis therapy to return to market under a special distribution program.

FDA Re-Approves Tysabri, Recommends Second-Line Use

Biogen Idec expects to re-launch the multiple sclerosis therapy in July.

Tysabri Re-Launch Approved With MRI Requirement

FDA clears Biogen Idec’s multiple sclerosis therapy to return to market under a special distribution program.

Related Content

Topics

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel